Psychogenics

Psychogenics company information, Employees & Contact Information

Explore related pages

Related company profiles:

PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients. Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.

Company Details

Employees
178
Address
215 College Rd, Paramus,new Jersey 07652,united States
Phone
(914) 406-8019
Email
in****@****ics.com
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
Paramus, New Jersey
Looking for a particular Psychogenics employee's phone or email?

Psychogenics Questions

News

PsychoGenics Launches an Updated Corporate Identity and Brand - Business Wire

PsychoGenics Launches an Updated Corporate Identity and Brand Business Wire

Back to the future: From target-selective drug design to AI-enabled polypharmacology - Endpoints News

Back to the future: From target-selective drug design to AI-enabled polypharmacology Endpoints News

Enrichment analysis of phenotypic data for drug repurposing in rare diseases - Frontiers

Enrichment analysis of phenotypic data for drug repurposing in rare diseases Frontiers

A systematic assessment of robustness in CNS safety pharmacology - British Pharmacological Society | Journals

A systematic assessment of robustness in CNS safety pharmacology British Pharmacological Society | Journals

PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain - Business Wire

PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain Business Wire

(PDF) Enrichment analysis of phenotypic data for drug repurposing in rare diseases - researchgate.net

(PDF) Enrichment analysis of phenotypic data for drug repurposing in rare diseases researchgate.net

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration - Business Wire

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration Business Wire

Top Psychogenics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant